6ER-046 Abstract withdrawn

<h3>Background and Importance</h3> Consolidation durvalumab following platinum-based chemoradiotherapy (CRT) is the global standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC), based on the results of the PACIFIC trial, that demonstrated a significant benefit in survival. Observational studies providing real-world evidence are essential to confirm these benefits. <h3>Aim and Objectives</h3> This study aims to evaluate the effectiveness and safety of durvalumab as consolidation therapy after concurrent CRT in the treatment of unresectable stage III non-small-cell lung cancer (NSCLC) at a tertiary care hospital. <h3>Material and Methods</h3> Observational, retrospective, single-centre study. All patients with NSCLC who received durvalumab after concurrent CRT from January 2018 to December 2023 were included. Socio-demographic, clinical and treatment-related data were collected using the hospital’s electronic medical record program and the Farmis-Oncofarm oncohaematological patient management software. To evaluate the treatment’s efficacy, we estimated progression-free survival (PFS) and overall survival (OS). <h3>Results</h3> A total of 52 patients were included. The most prevalent histologies were adenocarcinoma (62%) and squamous cell carcinoma (35%). All patients had PD-L1 expression ≥1%; half of them classified as high PD-L1 expressors (≥25%). The majority (71%) achieved a partial response following concurrent CRT; the remaining (29%) had stable disease. The overall median follow-up was 2 years. More than half of the patients (N=28, 54%) did not complete the full year of consolidation therapy; 15 due to disease progression and 13 due to toxicity. Median PFS was 24.3 months (95% confidence interval (CI), 14 to NA); the 12-month PFS rate was 67%, and the 18-month PFS rate was 58%. Improved PFS rates were observed in the high PD-L1 expressor subgroup, with a median PFS of 33.8 months compared to 23.5 months in patients with PD-L1&lt;25% (HR 0.67 (95% CI: 0.31–1.42)). Regarding OS, survival rates at 12, 18, and 24 months were 86.5%, 78.8%, and 71%, respectively. <h3>Conclusion and Relevance</h3> Our results demonstrate favourable outcomes with durvalumab consolidation therapy in real-world clinical practice, achieving higher PFS and OS rates compared to the PACIFIC trial. These superior outcomes may be attributed to the fact that our study exclusively included patients with PD-L1 expression ≥1%, whereas the PACIFIC trial included 20% of patients with no PD-L1 expression. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest